Albireo Current Assets from 2010 to 2023

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Albireo Pharma Current Assets yearly trend continues to be very stable with very little volatility. Current Assets are likely to grow to about 333.7 M this year. During the period from 2010 to 2023, Albireo Pharma Current Assets quarterly data regression pattern had range of 326,745,513 and median of 55,011,000. Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 26th of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).

Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 48.7 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0502, PPandE Turnover of 67.56 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement various Albireo Pharma Technical models . Check out Trending Equities.

Albireo Current Assets Breakdown

Showing smoothed Current Assets of Albireo Pharma with missing and latest data points interpolated. Current assets of Albireo Pharma include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Albireo Pharma. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.Albireo Pharma's Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Albireo Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 28.84 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Current Assets

Timeline

Albireo Current Assets Regression Statistics

	Arithmetic Mean	123,357,430
	Geometric Mean	64,599,372
	Coefficient Of Variation	98.64
	Mean Deviation	106,150,634
	Median	55,011,000
	Standard Deviation	121,684,484
	Range	326,745,513
	R-Value	0.88
	R-Squared	0.78
	Significance	0.00002829
	Slope	25,692,288

Albireo Current Assets History

	2023	333.7 M
	2022	309.3 M
	2021	268.9 M
	2020	261.9 M
	2019	141.8 M
	2018	167.7 M
	2017	55 M
	2016	30.9 M
	2014	6.9 M
	2013	24.9 M
	2012	40.1 M

Other Fundumenentals of Albireo Pharma

Net Current Assets as percentage of Total Assets

Albireo Pharma Current Assets component correlations

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's Current Assets, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for 2023
Current Assets	309.3 M	333.7 M
Net Current Assets as percentage of Total Assets	85.12	91.09
Average Assets	307 M	331.2 M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.83	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.73	ABCM	AbcamPLC		Pair Corr
-	0.7	ABTI	Alterola Biotech		Pair Corr
-	0.68	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.65	AADI	Aadi Bioscience	Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Check out Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Bond Directory Find actively traded corporate debentures issued by US companies
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Transaction History View history of all your transactions and understand their impact on performance
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Price Transformation Use Price Transformation models to analyze depth of different equity instruments across global markets
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	ETF Directory Find actively traded Exchange Traded Funds (ETF) from around the world

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

	Accounts Payable	Total Assets	Current Assets	Cash and Equivalents	Total Debt	Debt Current	Shareholders Equity	Total Liabilities	Current Liabilities	Tax Assets	Tax Liabilities
Accounts Payable		0.96	0.96	0.96	0.74	0.82	0.95	0.95	0.87	-0.28	-0.35
Total Assets	0.96		1.0	1.0	0.74	0.86	0.99	0.98	0.94	-0.32	-0.41
Current Assets	0.96	1.0		1.0	0.75	0.84	0.99	0.98	0.93	-0.3	-0.4
Cash and Equivalents	0.96	1.0	1.0		0.75	0.84	0.99	0.98	0.92	-0.3	-0.39
Total Debt	0.74	0.74	0.75	0.75		0.56	0.74	0.73	0.63	-0.22	-0.3
Debt Current	0.82	0.86	0.84	0.84	0.56		0.87	0.83	0.84	-0.44	-0.54
Shareholders Equity	0.95	0.99	0.99	0.99	0.74	0.87		0.96	0.9	-0.3	-0.39
Total Liabilities	0.95	0.98	0.98	0.98	0.73	0.83	0.96		0.96	-0.33	-0.43
Current Liabilities	0.87	0.94	0.93	0.92	0.63	0.84	0.9	0.96		-0.36	-0.47
Tax Assets	-0.28	-0.32	-0.3	-0.3	-0.22	-0.44	-0.3	-0.33	-0.36		0.98
Tax Liabilities	-0.35	-0.41	-0.4	-0.39	-0.3	-0.54	-0.39	-0.43	-0.47	0.98